当前位置:
X-MOL 学术
›
Drug Resist. Updat.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond
Drug Resistance Updates ( IF 15.8 ) Pub Date : 2024-01-29 , DOI: 10.1016/j.drup.2024.101062 Da-Qian Chen 1 , Yuhao Xie 2 , Lu-Qi Cao 3 , Joshua S Fleishman 2 , Yang Chen 4 , Tiesong Wu 5 , Dong-Hua Yang 6
Drug Resistance Updates ( IF 15.8 ) Pub Date : 2024-01-29 , DOI: 10.1016/j.drup.2024.101062 Da-Qian Chen 1 , Yuhao Xie 2 , Lu-Qi Cao 3 , Joshua S Fleishman 2 , Yang Chen 4 , Tiesong Wu 5 , Dong-Hua Yang 6
Affiliation
Multidrug resistance protein 7 (MRP7), also known as ATP-binding cassette (ABC) transporter subfamily C10 (ABCC10), is an ABC transporter that was first identified in 2001. ABCC10/MRP7 is a 171 kDa protein located on the basolateral membrane of cells. ABCC10/MRP7 consists of three transmembrane domains and two nucleotide binding domains. It mediates multidrug resistance of tumor cells to a variety of anticancer drugs by increasing drug efflux and results in reducing intracellular drug accumulation. The transport substrates of ABCC10/MRP7 include antineoplastic drugs such as taxanes, vinca alkaloids, and epothilone B, as well as endobiotics such as leukotriene C4 (LTC) and estradiol 17 β-D-glucuronide. A variety of ABCC10/MRP7 inhibitors, including cepharanthine, imatinib, erlotinib, tariquidar, and sildenafil, can reverse ABCC10/MRP7-mediated MDR. Additionally, the presence or absence of ABCC10/MRP7 is also closely related to renal tubular dysfunction, obesity, and other diseases. In this review, we discuss: 1) Structure and functions of ABCC10/MRP7; 2) Known substrates and inhibitors of ABCC10/MRP7 and their potential therapeutic applications in cancer; and 3) Role of ABCC10/MRP7 in non-cancerous diseases.
中文翻译:
ABCC10/MRP7 在抗癌耐药性及其他方面的作用
多药耐药蛋白 7 (MRP7),也称为 ATP 结合盒 (ABC) 转运蛋白亚家族 C10 (ABCC10),是 2001 年首次发现的 ABC 转运蛋白。ABCC10/MRP7 是一种 171 kDa 的蛋白,位于细胞。 ABCC10/MRP7 由三个跨膜结构域和两个核苷酸结合结构域组成。它通过增加药物外流介导肿瘤细胞对多种抗癌药物的多药耐药性,并减少细胞内药物积累。 ABCC10/MRP7的转运底物包括紫杉烷类、长春花生物碱和埃坡霉素B等抗肿瘤药物,以及白三烯C4(LTC)和雌二醇17β-D-葡萄糖醛酸苷等内生素。多种 ABCC10/MRP7 抑制剂,包括千金藤素、伊马替尼、厄洛替尼、塔利奎达和西地那非,可以逆转 ABCC10/MRP7 介导的多药耐药。此外,ABCC10/MRP7的存在与否也与肾小管功能障碍、肥胖等疾病密切相关。在这篇综述中,我们讨论:1)ABCC10/MRP7的结构和功能; 2)ABCC10/MRP7的已知底物和抑制剂及其在癌症中的潜在治疗应用; 3) ABCC10/MRP7 在非癌症疾病中的作用。
更新日期:2024-01-29
中文翻译:
![](https://scdn.x-mol.com/jcss/images/paperTranslation.png)
ABCC10/MRP7 在抗癌耐药性及其他方面的作用
多药耐药蛋白 7 (MRP7),也称为 ATP 结合盒 (ABC) 转运蛋白亚家族 C10 (ABCC10),是 2001 年首次发现的 ABC 转运蛋白。ABCC10/MRP7 是一种 171 kDa 的蛋白,位于细胞。 ABCC10/MRP7 由三个跨膜结构域和两个核苷酸结合结构域组成。它通过增加药物外流介导肿瘤细胞对多种抗癌药物的多药耐药性,并减少细胞内药物积累。 ABCC10/MRP7的转运底物包括紫杉烷类、长春花生物碱和埃坡霉素B等抗肿瘤药物,以及白三烯C4(LTC)和雌二醇17β-D-葡萄糖醛酸苷等内生素。多种 ABCC10/MRP7 抑制剂,包括千金藤素、伊马替尼、厄洛替尼、塔利奎达和西地那非,可以逆转 ABCC10/MRP7 介导的多药耐药。此外,ABCC10/MRP7的存在与否也与肾小管功能障碍、肥胖等疾病密切相关。在这篇综述中,我们讨论:1)ABCC10/MRP7的结构和功能; 2)ABCC10/MRP7的已知底物和抑制剂及其在癌症中的潜在治疗应用; 3) ABCC10/MRP7 在非癌症疾病中的作用。